
There was no observed increase in risk to short- or mid-term clinically relevant infections despite the low levels of immunoglobulins.

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.
She has a BA in English language and literature from Rutgers University. You can connect with Julia on LinkedIn.

There was no observed increase in risk to short- or mid-term clinically relevant infections despite the low levels of immunoglobulins.

Veligrotug-vvze (Lumvoa; Viridian Therapeutics) is the first treatment for thyroid eye disease (TED) that has been approved by the FDA with labeling that includes data for both active and chronic TED.

Lower rates of successful discharge were reported in home health care patients whose care was interrupted by flooding related to hurricanes.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Spending on health expenditures will make up 20.6% of gross domestic product, according to a federal report.

Interviews with patients living with generalized myasthenia gravis (MG) in the US revealed areas of increased burden in these patients.

Patients with early relapsing multiple sclerosis (MS) were able to switch to ocrelizumab after suboptimal responses to other disease-modifying therapies.

The 2026 conference, held in Baltimore, Maryland, offered expert insight into the past and future of sleep medicine.

More short-term injections were needed to maintain visual outcomes in patients who lost their co-payment assistance.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A meta-analysis evaluated the efficacy of various monoclonal antibodies in treating patients with myasthenia gravis (MG).

Mobile health models that include artificial intelligence and smartphone imaging can help address gaps in early detection.

Changes in PrEP for HIV expand choice and reduce risk as new research continues to look for an elusive cure.

Patients with narcolepsy type 1 reported high disease burden, including chronic symptoms like hallucinations, sleep paralysis, and difficulty concentrating.

Late-breaking abstracts presented during the Sleep 2026 Annual Meeting provided new data on how the time of year could change sleep duration and the efficacy of low-sodium oxybate.

The American Heart Association’s Life’s Essential 8 indicates that the key to a healthy heart is through the treatment of sleep, including in obstructive sleep apnea (OSA) and narcolepsy.

The use of artificial intelligence (AI) in sleep medicine could cause pitfalls on the practical and training ends, affecting patient care.

A session held during the Sleep 2026 Annual Conference focused on how wearables played a role in obstructive sleep apnea.

Abstracts presented during the Sleep 2026 Annual Meeting focused on the potential benefits of using oveporexton in narcolepsy type 1.

The conference, set to take place in Baltimore, Maryland, will feature 4 days of sessions focusing on sleep medicine and how it affects overall health.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The use of in-hospital statins in older adults admitted to an acute geriatric ward was associated with in-hospital mortality.

The treatment worked in patients with generalized myasthenia gravis (gMG) regardless of previous immunosuppressive treatment or concomitant use of other gMG treatments.

Despite increases in influenza vaccine rates before the pandemic in the Bronx, rates have decreased between 2020 and 2023.

A total of 2288 cases of measles were confirmed in the US for the full year of 2025, suggesting that the cases are set to double in 2026.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The fluocinolone acetonide intravitreal implant showed durable improvements in anatomical and functional outcomes over a follow-up period of 36 months.

Most patients achieved stable or reduced lesion burden and the treatment was well tolerated by patients.

James F. Howard, MD, discusses what he believes will be the next steps in treating myasthenia gravis.

Asthma and Allergy Awareness Month shines light on the ways that asthma can affect long-term health.

Published: October 19th 2025 | Updated: October 22nd 2025

Published: August 18th 2025 | Updated: August 25th 2025

Published: August 19th 2025 | Updated: August 22nd 2025

Published: September 26th 2024 | Updated: October 1st 2024

March 21st 2025